Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


IntegraGen Works with the Fondation Autisme to create a DNA sample databank

Paris, France; 24 May 2005….. IntegraGen, the personalised medicines company, announced today that it will be using DNA samples collected by the newly formed Fondation Autisme to validate its genetic test for autism, expected to become available in 2006. The company is supporting the French-based Fondation with a donation and by providing assistance in creating a databank and repository of DNA samples collected from families with an autistic child. These samples, along with accompanying clinical data, will be freely available to the scientific community to stimulate collaborative research with a view to determining the genetic causes of autism.

Jan Mous, CEO at IntegraGen said: “With IntegraGen’s help, the Fondation Autisme aims to collect DNA samples from 200 French families with autistic children over the next 12 months creating an invaluable resource for the global autism research community. IntegraGen will be one of the first organisations to benefit from the databank, as it will help us to validate our genetic test for autism, significantly speeding its progress into the clinic. Autism is widely thought to be increasing in prevalence and may affect as many as one in 150 children. There is agreement within the clinical and research community that earlier diagnosis increases the chances for a successful therapy. A genetic diagnosis, as developed by IntegraGen, will be a first step forward in this direction.”

To create the sample databank, the Fondation Autisme has also formed a partnership with Cure Autism Now (CAN), a foundation committed to accelerating the pace of biomedical research in autism, and Généthon, a French-based genetic research institute that offers expertise in cell immortalisation, isolation of DNA and storage of the samples and cell lines.

Using samples from US families provided by the Autism Genetics Resource Exchange (AGRE), a part of CAN, researchers at IntegraGen have already identified 12 genes associated with autism and the first results of this work have been submitted for publication. The Company has used this information to develop its genetic test for susceptibility to autism. The test is currently undergoing extensive clinical validation and is expected to be available in 2006. Earlier and more accurate diagnosis of autism in young children will allow direct interventional therapy to be given at the earliest possible age, when it is of greatest potential benefit.

About IntegraGen
IntegraGen SA uses its unique genomic analysis expertise to identify genes associated with complex diseases and to develop diagnostic and predictive genetic tests. The Company applies its innovative gene mapping technology, GenomeHIP® (Genome Hybrid Identity Profiling), to rapidly discover genetic loci that are implicated in complex, multi-factorial diseases. GenomeHIP® is a major advance that overcomes the limitations of existing marker based familial linkage study methods.

IntegraGen is applying its discoveries to develop a series of innovative IntegraTests™ and is poised to become a leader in the rapidly growing field of predictive medicine. The Company will be a fully integrated provider of genetic tests that can be used to predict, prevent, diagnose and tailor personalized treatments for complex diseases. Testing will be provided as a service through Expert Centers, which will also provide expert analysis and genetic counseling from an accredited MD-geneticist. The Company’s first Expert Center has been established in Bonn, Germany, to provide the Company’s first testing service for MODY diabetes (Mature Onset Diabetes of the Young) testing. The Bonn center will become fully operational in April this year.

The Company's strategy is to develop molecular diagnostic tools for selected disease areas with high medical need. IntegraGen's in-house programs are focused on neurological disorders, including autism and bi-polar disorder, and metabolic disorders, such as obesity and type 2 diabet

Publisher Contact Information:

IntegraGen SA
+33 (0)1 60 91 09 00

Company profile of IntegraGen SA
Past press releases of IntegraGen SA.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

May 17€4.0MBiopharmaceuticals
May 16€15.0MPayment software
May 16€4.0MInternet services
May 16€80.0MConsumer electronics
May 16€6.3MImaging
May 16€13.0MInternet services
May 16€34.5MBiotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.